Rosiglitazone safety questioned, again
Links shared publicly online about this topic.
- 1,811total visits
Rosiglitazone safety questioned, again
View full resource at theheart.org
Tags: Heart Failure, Diabetes Type 2 Medication, Diabetes Medication, Drug, Avandia, Avandamet, Avandaryl, Actos
Most Recently Shared on August 19, 2009 at 8:16 pm By:
heartwire: Rosiglitazone safety questioned, again, this time in population-based study http://bit.ly/3q9XKE
FDA will consider halting TIDE, based on advisory committee's input
theheart.org — “Responding to a report issued by the Senate Finance Committee, FDA commissioner Margaret Hamburg says the agency is convening a joint advisory committee meeting to get expert opinion on all the recent evidence questioning rosiglitazone's cardiovascular safety profile—if need be, the agency could stop the much-debated TIDE trial.” View full resource at theheart.org
Most Recently Shared on July 14, 2010 at 1:20 pm By:
#Avandia IoM's Steve Goodman and Ruth Faden present their take on ethics of a trial like TIDE, something FDA asked for. http://bit.ly/cE7Pp3
Day one data deluge at FDA rosiglitazone meeting | theheart.org
theheart.org — “A marathon 11-hours of presentations have likely left the joint Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committee reeling in confusion. Day two promises more time for questions and reflection before the all-important vote.” View full resource at theheart.org
Most Recently Shared on July 14, 2010 at 12:53 am By:
Day one: Data deluge at FDA rosiglitazone review provides more questions than answers: A marathon 11-hours of pres... http://bit.ly/bXoUOV
Day one data deluge at FDA rosiglitazone meeting | theheart.org
theheart.org — “A marathon 11-hours of presentations have likely left the joint Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committee reeling in confusion. Day two promises more time for questions and reflection before the all-important vote.” View full resource at theheart.org
Most Recently Shared on July 14, 2010 at 12:33 am By:
Full story: Day one: Data deluge at FDA rosiglitazone review provides more questions than answers http://bit.ly/bMAGWC
Waiting for answers on TIDE
theheart.org — “The FDA's response to a Senate investigation of rosiglitazone has led to new speculation about the likelihood that the head-to-head TIDE trial will continue and just what would be lost or gained if it were halted. Also alluded to in Commissioner Hamburg's letter are questions of whether patients in the trial have been made well aware of the safety concerns. Not everyone agrees.” View full resource at theheart.org
Most Recently Shared on July 13, 2010 at 7:44 pm By:
#Avandia - Graham is discussing informed consent in TIDE. An issue heartwire covered in depth: http://bit.ly/dl63Zm
Scientific Leaders Urge Type 2 Diabetes Patients To Remain On Their Prescribed Medications Unless Instructed Otherwise By Their Health Care Provider
medicalnewstoday.com — “Over the past several weeks reports have again surfaced regarding the cardiovascular safety of the diabetes drug rosiglitazone. While some analyses have suggested an increased cardiovascular risk” View full resource at medicalnewstoday.com
Most Recently Shared on July 13, 2010 at 2:42 pm By:
MedicalNewsToday: Scientific Leaders Urge Type 2 Diabetes Patients To Remain On Their: http://bit.ly/afcd7A Full http://bit.ly/cEH4xj
Waiting for answers on TIDE
theheart.org — “The FDA's response to a Senate investigation of rosiglitazone has led to new speculation about the likelihood that the head-to-head TIDE trial will continue and just what would be lost or gained if it were halted. Also alluded to in Commissioner Hamburg's letter are questions of whether patients in the trial have been made well aware of the safety concerns. Not everyone agrees.” View full resource at theheart.org
Most Recently Shared on April 22, 2010 at 7:40 pm By:
Churning over TIDE: Experts mull informed consent and repercussions of potential halt: The FDA's response to a Sen... http://bit.ly/deqvAi
FDA will consider halting TIDE, based on advisory committee's input
theheart.org — “Responding to a report issued by the Senate Finance Committee, FDA commissioner Margaret Hamburg says the agency is convening a joint advisory committee meeting to get expert opinion on all the recent evidence questioning rosiglitazone's cardiovascular safety profile—if need be, the agency could stop the much-debated TIDE trial.” View full resource at theheart.org
Most Recently Shared on April 19, 2010 at 9:00 pm By:
FDA responds to Senate concerns over rosiglitazone; will "reassess" TIDE trial: Responding to a report issued by t... http://bit.ly/b7InFl
Senate report questions safety of rosiglitazone
endocrinetoday.com — “A new report released over the weekend by the United States Senate Committee on Finance brings more attention to the diabetes drug rosiglitazone” View full resource at endocrinetoday.com
Most Recently Shared on February 22, 2010 at 10:15 pm By:
Senate report questions safety of diabetes drug rosiglitazone http://ow.ly/1a5D2
WebMD News Watch: Avandia Safety
blogs.webmd.com — “Trustworthy breaking medical news and health information.” View full resource at blogs.webmd.com
Most Recently Shared on February 22, 2010 at 7:28 pm By:
Breaking News: Avandia Safety: Safety questions about the diabetes drug Avandia once again are in the news, thanks... http://bit.ly/ax77JN
GSK, FDA under fire in new senate report on Avandia
theheart.org — “A new Senate report has rekindled debate about the cardiovascular safety of GlaxoSmithKline's diabetes agent rosiglitazone, stating that there are” View full resource at theheart.org
Most Recently Shared on February 22, 2010 at 2:05 pm By:
New senate report puts Avandia safety in spotlight again: A new senate report has rekindled debate about the cardi... http://bit.ly/90v8fn
Supplement safety questioned - again
nutraingredients-usa.com — “Dietary supplements are again the focus of attention in recent articles published in The Wall Street Journal and New York Times – and once more the products are portrayed in a less than flattering light.” View full resource at nutraingredients-usa.com
Most Recently Shared on September 9, 2009 at 11:31 pm By:
Evelyn Tribole Active Health Library, Nutritionist, and Dietitian
Supplement safety questioned - again in today's WSJ. http://ow.ly/oK5N
Advertisement
